Vanguard Capital Management
RPRX icon

Vanguard Capital Management’s Royalty Pharma RPRX Stock Holding History

Vanguard Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271M Buy
4,826,617
+294,731
+7% +$15.3M 0.01% 965
2026
Q1 		$217M Buy
+4,531,886
New +$198M 0.01% 1018

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's RPRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Royalty Pharma (RPRX) stake by 6.5% in Q2 2026, buying an estimated $15.3M and bringing the position to 4,826,617 shares worth $271M. The position accounts for 0.01% of the portfolio, ranked #965.

Vanguard Capital Management first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 639 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Vanguard Capital Management held 4,826,617 shares of Royalty Pharma worth $271M as of Q2 2026.
  • Vanguard Capital Management bought 294,731 Royalty Pharma shares in Q2 2026, an estimated $15.3M.
  • Royalty Pharma made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #965 holding.
  • Vanguard Capital Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 639 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.